coronavirus
cov
caus
highli
preval
diseas
human
anim
fatal
outbreak
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
highlight
threat
pose
uniqu
viru
subfamili
howev
specif
drug
approv
treat
covassoci
diseas
date
cov
proteas
play
pivot
role
viral
gene
express
replic
highli
complex
cascad
involv
proteolyt
process
replicas
polyprotein
attract
target
drug
design
review
summar
recent
advanc
biolog
structur
studi
togeth
develop
inhibitor
target
cov
proteas
particularli
main
proteas
pro
could
help
develop
effect
treatment
prevent
cov
infect
outbreak
sever
acut
respiratori
syndrom
sar
epidem
worldwid
winter
summer
coronavirus
cov
long
consid
caus
mere
mild
symptom
human
despit
attribut
sever
diseas
anim
dominguez
et
al
drosten
et
al
francopared
et
al
kuiken
et
al
rota
et
al
sar
epidem
caus
sar
coronaviru
sarscov
result
total
death
case
infect
dominguez
et
al
francopared
et
al
anoth
new
cov
call
middl
east
respiratori
syndrom
coronaviru
merscov
emerg
origin
middl
east
zaki
et
al
accord
world
health
organ
new
cov
thu
far
result
case
infect
caus
death
http
wwwwhointemergenciesmerscoven
sarsand
merscov
zoonot
origin
woo
et
al
woo
et
al
chan
et
al
ge
et
al
lu
et
al
st
john
et
al
strongli
suggest
anim
cov
remain
potenti
threat
human
howev
specif
drug
approv
treat
covassoci
diseas
date
wake
sar
outbreak
indepth
research
reveal
multipl
aspect
life
cycl
cov
infect
cov
mainli
take
advantag
spike
protein
bind
receptor
attach
host
cell
membran
ng
et
al
upon
enter
host
cell
cov
start
releas
genom
rna
subsequ
express
two
polyprotein
respons
viral
replic
transcript
respect
requir
hijack
host
ribosom
facilit
translat
two
result
polyprotein
process
two
viralencod
proteas
matur
nonstructur
protein
nsp
host
gene
express
suppressor
function
interact
two
host
protein
multidomain
complex
transmembran
protein
pro
primas
singlestrand
rnabind
protein
rnadepend
rna
polymeras
rna
helicasentpaserna
exoribonucleas
uridylatespecif
endoribonucleas
cornillezti
et
al
te
velthui
et
al
ivanov
et
al
narayanan
et
al
snijder
et
al
sutton
et
al
ziebuhr
nsp
assembl
replicationtranscript
complex
facilit
viral
rna
replic
transcript
zhao
et
al
current
sever
viral
protein
consid
candid
target
drug
develop
includ
proteas
helicas
rdrp
methyltransferas
involv
aforement
viral
life
cycl
adedeji
sarafiano
among
pro
import
target
owe
essenti
role
process
polyprotein
ziebuhr
et
al
review
focu
recent
progress
develop
inhibitor
proteas
particular
focu
pro
tabl
papainlik
proteas
pl
pro
figur
exist
function
domain
within
larg
also
encod
ubiquitinlik
fold
domain
sarscovuniqu
domain
transmembran
domain
lee
et
al
pl
pro
recogn
specif
site
compris
consensu
cleavag
sequenc
lxgg
lee
et
al
proteolyt
cleavag
peptid
bond
glycin
residu
result
releas
viral
polyprotein
critic
step
viral
replic
ziebuhr
et
al
pl
pro
found
deubiquitin
deinterferon
stimul
geneyl
isgyl
function
help
viru
escap
host
immun
respons
via
interferon
signal
pathway
baezsanto
et
al
merscov
pl
pro
report
protect
polyprotein
cleavag
interferon
regulatori
factor
pathway
sun
et
al
pl
pro
differ
cov
speci
may
also
vari
substrat
specif
lee
et
al
may
contribut
difficulti
develop
widespectrum
drug
target
cov
nonetheless
molecul
found
effect
inhibit
cov
infect
includ
zinc
ion
zn
zinc
conjug
inhibitor
report
target
pl
pro
han
et
al
howev
inhibitor
appear
uniqu
metal
ion
thu
far
found
possess
inhibitori
capac
baezsanto
et
al
addit
thiopurin
compound
could
suppress
activ
pl
pro
coval
bind
cystein
residu
activ
site
chen
et
al
natur
product
also
found
inhibit
pl
pro
activ
includ
tanshinon
park
et
al
diarylheptanoid
park
et
al
geranyl
flavonoid
cho
et
al
recent
sever
crystal
structur
sarscov
pl
pro
complex
inhibitor
report
ratia
et
al
ghosh
et
al
ghosh
et
al
baezsanto
et
al
figur
sarscovpl
pro
contain
two
block
loop
proven
vital
block
access
catalyt
site
lee
et
al
upon
bind
loop
inhibitor
caus
local
conform
chang
subsequ
block
access
substrat
bind
catalyt
site
lee
et
al
cov
genom
encod
two
overlap
polyprotein
design
mukherje
et
al
polyprotein
cleav
viral
proteas
yield
matur
nsp
mention
assembl
replicationtranscript
complex
essenti
viral
replic
pro
key
enzym
involv
proteolysi
process
ziebuhr
et
al
respons
cleavag
site
polyprotein
ziebuhr
owe
domin
indispens
role
polyprotein
process
pro
thu
emerg
import
target
anticov
drug
design
mani
inhibitor
identifi
date
peptidomimet
ghosh
et
al
yang
et
al
keton
shao
et
al
pyrimidin
ramajayam
et
al
previous
review
detail
mukherje
et
al
zhao
et
al
zhao
et
al
adedeji
sarafiano
therefor
focu
recent
progress
inhibitor
drug
discoveri
last
two
year
mani
research
group
exert
continu
effort
develop
inhibitor
target
cov
pro
figur
chen
et
al
zhou
et
al
report
new
class
isatin
deriv
pro
inhibitor
zhou
et
al
base
result
liu
et
al
start
investig
potenti
use
isatin
deriv
design
effici
inhibitor
cov
pro
liu
et
al
studi
seri
isatin
deriv
design
synthes
assess
vitro
enzymat
assay
fluorogen
substrat
peptid
among
isatin
deriv
carboxamid
group
substitut
seri
sulfonamid
group
show
inhibit
pro
micromolar
rang
assist
structurebas
lead
compound
design
author
effect
optim
isatin
deriv
obtain
optim
compound
name
ic
figur
comparison
differ
substitut
group
reach
conclus
isatin
coupl
methyl
posit
could
dramat
promot
inhibitori
activ
could
facilit
lead
compound
develop
akaji
group
report
novel
inhibitor
decahydroisoquinolin
scaffold
could
target
sarscov
pro
shimamoto
et
al
figur
previou
studi
show
hydrophob
interact
site
import
substrateinhibitor
bind
new
inhibitor
design
connect
substratebas
inhibitor
cyclohexyl
group
locat
site
atom
posit
main
chain
approach
could
maintain
hydrophob
interact
site
kept
imidazol
aldehyd
group
requir
configur
respect
bind
author
synthes
seri
decahydroisoquinolin
deriv
show
moder
clear
inhibitori
activ
sarscov
pro
xray
crystallograph
studi
reveal
decahydroisoquinolin
scaffold
insert
larg
pocket
occupi
pocket
hold
termin
aldehyd
tightli
insid
activ
site
cleft
result
observ
inhibitori
activ
previous
group
investig
conserv
cov
pro
across
speci
structur
analys
reveal
substratebind
pocket
variou
cov
pro
highli
conserv
led
concept
widespectrum
inhibitor
target
cov
structurebas
drug
design
identifi
lead
compound
name
potent
inhibitori
activ
pro
test
figur
recent
wong
group
analyz
substrat
specif
pro
site
among
sever
cov
found
pro
similar
substrat
specif
find
facilit
design
broadspectrum
peptidomimet
inhibitor
variou
cov
pro
identifi
new
peptidyl
compound
cbztsavlqcn
coupl
nitril
warhead
carboxybenzyl
cbz
group
cterminu
nterminu
peptid
respect
chuck
et
al
enzymat
assay
reveal
could
inhibit
pro
six
differ
speci
cov
solv
crystal
structur
enzym
complex
inhibitor
indic
ntermin
cbz
protect
group
could
improv
interact
inhibitor
proteas
kim
et
al
also
design
seri
peptidyl
compound
target
felin
coronavirus
fcov
felin
calicivirus
fcv
kim
et
al
report
compound
name
display
inhibitori
activ
fcov
fcv
strain
cell
cultur
figur
inhibitori
effect
confirm
mous
model
base
liver
histopatholog
analysi
addit
design
zinc
ion
dual
inhibitor
felin
infecti
periton
viru
fipv
pro
biochem
data
show
zn
could
serv
irrevers
inhibitor
noncompetit
inhibitor
respect
solv
crystal
structur
fipv
pro
complex
two
inhibitor
demonstr
potenti
synergist
activ
achiev
enhanc
inhibitori
effect
find
provid
new
approach
design
anticov
drug
hand
gain
better
understand
cleavag
mechan
cov
pro
could
help
provid
new
direct
design
inhibitor
dimer
essenti
step
pro
matur
subsequ
catalysi
shi
et
al
report
mechan
cov
pro
control
dimermonom
switch
shi
et
al
specif
mutat
residu
dimer
interfac
shown
disturb
dimer
pro
paasch
et
al
could
revert
via
substrateinduc
conform
chang
moreov
structur
studi
reveal
establish
new
intermolecular
interact
requir
domain
iii
compos
globular
cluster
five
helic
anand
et
al
alter
orient
suggest
pro
abl
toler
larg
conform
chang
without
loss
enzymat
activ
impli
intramolecular
commun
regul
exist
within
pro
structur
thu
better
understand
underli
mechan
might
aid
structurebas
anticov
drug
design
paasch
et
al
report
substrat
bindinginduc
zwitterion
format
activ
site
sarscov
pro
paasch
et
al
discov
cy
zwitterion
state
essenti
effici
proteolyt
activ
foster
substrat
bind
rather
inhibitor
bind
enhanc
substrat
specif
freeenergi
calcul
delin
substrat
bind
could
promot
proton
transfer
reaction
reduc
energi
neutral
zwitterion
state
impli
develop
antivir
agent
abil
substrat
trigger
zwitterion
state
may
altern
approach
drug
design
wake
outbreak
sar
mer
cov
emerg
lifethreaten
pathogen
human
zoonot
origin
also
send
warn
potenti
emerg
new
deadli
cov
via
interspeci
transmiss
thu
mani
inhibitor
develop
prevent
cov
infect
howev
problem
toxic
abil
enter
cell
nonspecif
instabl
particularli
peptidederiv
inhibitor
among
other
still
major
hurdl
overcom
lead
compound
therefor
investig
requir
develop
effect
treatment
prevent
cov
infect
requir
tackl
problem
multipl
approach
